跳至主要内容
临床试验/2025-524602-15-00
2025-524602-15-00招募中2 期

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

Hospices Civils De Lyon1 个研究点 分布在 1 个国家目标入组 165 人开始时间: 2026年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
165
试验地点
1
主要终点
Derived from the PET data, the binding potential (BPND) parametric maps will be calculated using compartmental modelling techniques. Derived from the MRI data, the LC will be defined with a semi-automatic method from the MRI sequence sensitive to neuromelanin, and its signal intensity will be calculated for each participant as previously described (Laurencin et al., 2024a)

研究概览

简要总结

The primary objective of the NA2C-PET-MRI study is to evaluate in vivo, using the radiotracer [¹¹C]ORM-13070, the effect of normal aging and Parkinson's disease on the availability of α₂C-adrenergic receptors in the human brain.

研究设计

分配方式
Na
主要目的
[11c]orm-13070
盲法
None

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Healthy volunteers : Age between 20 years and 80 years
  • Patients : Weight between 40kg and 100kg
  • Patients : With an idiopathic Parkinson’s disease (Dopa-sensitive)
  • Patients : Without head trauma history including loss of consciousness superior to 30 minutes
  • Patients : Without associated neurological pathology
  • Patients : With highly effective contraception for women of childbearing age
  • Patients : Affiliated to a social security or similar scheme
  • Patients : Not subject to any legal protection measures
  • Patients : Participant must have signed an informed consent document
  • Healthy volunteers : Weight between 40kg and 100kg
  • Healthy volunteers : Without neurologic or psychiatric history
  • Healthy volunteers : Without head trauma history including loss of consciousness superior to 30 minutes
  • Healthy volunteers : With highly effective contraception for women of childbearing age
  • Healthy volunteers : Affiliated to a social security or similar scheme
  • Healthy volunteers : Not subject to any legal protection measures
  • Healthy volunteers : Participant must have signed an informed consent document
  • Patients : Age between 40 years and 80 years

排除标准

  • Subject receiving (or having received in the last month) somatic medication with cerebral or psychological effects (e.g., antihistamines)
  • Persons receiving psychiatric care
  • Persons admitted to a health or social care facility for purposes other than research
  • Subjects with a current or past dependence on alcohol or any other addictive substance according to DSM-IV-TR criteria, with the exception of nicotine and caffeine
  • Subjects already participating in another biomedical research project or who have participated in a study using ionizing radiation within the past year
  • Pregnant woman parturient or breastfeeding
  • MRI contraindications : people using pacemaker or insulin pumps, with implanted or embedded metal objects in the head or body, claustrophobic, with neurosensory stimulators or implantable defibrillators, with cochlear implants, with ferromagnetic foreign bodies in the eye or brain close to nerve structures, agitation of the subject (uncooperative or agitated subjects), ventriculoperitoneal neurosurgical shunt valves, dental appliances
  • Subject with a contraindication to PET scans at the ORM : hypersensitivity to the active substance or to any of the excipients (sodium chloride)
  • Subjects who are unable to understand or complete the study (language barrier, obvious lack of motivation, etc.) as judged by the investigator
  • Subjects who do not agree to be informed in the event of an incidental finding of an abnormality on MRI or during neuropsychological assessment
  • Persons deprived of their liberty by judicial or administrative decision

研究组 & 干预措施

[11C]ORM-13070

Test

干预措施: [11C]ORM-13070 (Drug)

结局指标

主要结局

Derived from the PET data, the binding potential (BPND) parametric maps will be calculated using compartmental modelling techniques. Derived from the MRI data, the LC will be defined with a semi-automatic method from the MRI sequence sensitive to neuromelanin, and its signal intensity will be calculated for each participant as previously described (Laurencin et al., 2024a)

Derived from the PET data, the binding potential (BPND) parametric maps will be calculated using compartmental modelling techniques. Derived from the MRI data, the LC will be defined with a semi-automatic method from the MRI sequence sensitive to neuromelanin, and its signal intensity will be calculated for each participant as previously described (Laurencin et al., 2024a)

次要结局

  • Correlation coefficients between regional BPND and contrast ratio in the LC (signal intensity).
  • Correlation coefficients between PET-MRI indices of the noradrenergic system (α₂C BPND and contrast ratio in the LC) and performance: · cognitive: MoCA, TMT A/B, Stroop; · memory: RL/RI-16, digit memory (span); · Language: verbal fluency; · Visuospatial: VOSP score; · Olfactory: Sniffin' Sticks (TDI score); · Affective/Mood: apathy (LARS), depression (BDI-II), anxiety (STAI), fatigue (PDFS-16), impulsivity (UPPS) · Sleep: Epworth, RBDSQ; · Dysautonomic: SCOPA-AUT score; · Pain (EVA score)
  • Correlation coefficients between PET-MRI indices of the noradrenergic system (α₂C BPND and contrast ratio in the LC) and clinical and behavioral variables: Disease severity; Cognition; Memory; Language; Visuospatial ability; Olfactory, Affective/Mood; Sleep ; Dysautonomia ; Pain

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Dr Chloé LAURENCIN

Scientific

Hospices Civils De Lyon

研究点 (1)

Loading locations...

相似试验